Daré Bioscience Q3 revenue jumps on R&D services and product sales, net loss narrows
Overview
US women's health biotech's Q3 revenue rose sharply yr/yr, driven by R&D services and product sales
Net loss narrowed compared to prior year
Company highlighted commercial progress for DARE to PLAY and Flora Sync LF5
Outlook
Company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q4 2026
Company does not expect product revenue to be material during 2026
Revenue from DARE to RECLAIM intravaginal ring targeted to begin in 2027
Result Drivers
R&D SERVICES REVENUE - Q3 revenue increase was primarily due to research and development services under agreements with the Gates Foundation
FLORA SYNC LF5 SALES - Revenue from sales of Flora Sync LF5 began in July 2026, contributing to Q3 revenue
LOWER R&D EXPENSES - Decreased R&D expenses reflected lower costs for several development programs, including Sildenafil Cream, DARE-LARC1, and Ovaprene
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $0.18 |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Dare Bioscience Inc is $8.00, about 1,116.9% above its November 13 closing price of $0.66
Reuters Recommended Reads
Nov 13 - Nutritional supplements maker Natural Alternatives' Q1 revenue falls on private-label sales drop
Nov 13 - Indaptus Therapeutics Q3 net loss narrows as R&D costs fall
Nov 16 - AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)